SCHEMBL5800611

SCHEMBL5800611

Cc1ccc(N2CCC(C(=O)O)CC2)cc1C

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 10/20 0.55
KDM4E B2RXH2 2/20 0.53
USP2 O75604 1/20 0.53
HPGD P15428 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ADRB1 P08588 1/20 0.51
GAA P10253 2/20 0.51
MAPT P10636 1/20 0.51
PDK2 Q15119 1/20 0.48
AKR1C3 P42330 1/20 0.48
TRPV1 Q8NER1 1/20 0.47
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21533508 0.88 NOTUM (0.65) NOTUMKDM4EUSP2HPGDNPSR1
SCHEMBL7210470 0.86 LGMN (0.54) NOTUMKDM4EUSP2HPGDNPSR1
SCHEMBL31381229 0.86 NOTUM (0.56) NOTUMKDM4EUSP2HPGDNPSR1
SCHEMBL3820949 0.86 NOTUM (0.56) NOTUMKDM4EUSP2HPGDNPSR1
SCHEMBL26706694 0.83 NOTUM (0.51) NOTUMKDM4EUSP2HPGDNPSR1
SCHEMBL4412651 0.83 NOTUM (0.63) NOTUMPDK2
SCHEMBL2070467 0.81 NOTUM (0.57) NOTUMKDM4EUSP2HPGDNPSR1
SCHEMBL3098998 0.81 MAPT (0.57) NOTUMHPGDNPSR1GAAMAPT
SCHEMBL21533588 0.81 LGMN (0.69) KDM4EMAPTPDK2SMN1; SMN2
SCHEMBL3104064 0.80 MAPT (0.48) KDM4EUSP2NPSR1HSD17B10ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US claimed
WO-2006058338-A2 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 WO claimed
WO-2006058338-A2 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 WO disclosed
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor VDAC1, TRPV1, HVCN1 NOTUM 3548/4885KDM4E 2664/4885USP2 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.